Bangalore, Nov 11, 2009: Duke University has entered into a partnership with Jubilant Organosys' subsidiary Jubiliant Biosys to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies.

Jubilant is one of India's top integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company.

As part of the partnership, Duke and Jubilant will work towards jointly selecting and managing a portfolio of translational research projects that leverages expertise and thought leadership from Duke University scientists and development capabilities including funding from Jubilant.

Both the firms will work together over five years to develop a portfolio of 4-5 technologies at steady state over the period of collaboration.

A prepared joint release said the non-exclusive collaboration will apply Jubilant's proprietary portfolio of drug development capabilities toward discoveries made by the faculty of the Duke University School of Medicine. Royalties paid to Duke would be churned back into support of promising faculty discovery research and further investments in translational technologies.

“This project and relationship will further the shared commitments of Duke Medicine and Jubilant to innovative translational medicine strategies and brings together incredibly strong complementary expertise in science and research & development,” said Victor J. Dzau, Chancellor for Health Affairs at Duke, and CEO, Duke University Health System.

Dzau made the announcement while attending the World Economic Forum's India Economic Summit in India's capital New Delhi.

“This partnership is a continued demonstration of Jubilant’s global partnering efforts to identify and deliver affordable and enabling innovation and health care solution to the global pharmaceutical industry and patients worldwide. Duke Medicine is the ideal academic health sciences partner for us to pursue our intent of building a world-class research capability as an overlay to our network of healthcare facilities that provide high quality, low cost care for economically weaker section and rural communities in India,” said Shyam Bhartia, Chairman & Managing Director & Hari Bhartia, Co-chairman and Managing Director for Jubilant Organosys. “Duke University uniquely understands the importance of eliminating global health disparities and is recognized globally for its excellence in conducting translational research that will, in this case, help us work together towards improving the high quality and affordable care for patients in India.”